Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The objective of this study is to evaluate safety and performance of the COOLSTAT® Transnasal Thermal Regulating Device in reducing temperature in a population of febrile subjects who meet the inclusion/exclusion criteria.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Transnasal Thermal Regulating Device | Experimental | Consented subjects will undergo cooling via transnasal thermal regulating device for a period of 8 to 24 hours |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Transnasal Thermal Regulating Device | Device | Placement of transnasal thermal regulating device to reduce temperature in febrile patients for a period of 8 to 24 hours |
|
| Measure | Description | Time Frame |
|---|---|---|
| Cooling Performance | Ability of transnasal thermal regulating device to reduce core body temperature within 4 hours of initiation | 4 hours |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Neeraj Badjatia, MD MS | Univ of Maryland | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| MedStar Washington Hospital Center | Washington D.C. | District of Columbia | 20010 | United States | ||
| University of Maryland Medical Center |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 37498457 | Derived | Arnold S, Armahizer M, Torres LF, Tripathi H, Tandri H, Chang JJ, Choi HA, Badjatia N. Minimizing Shivering During Targeted Normothermia: Comparison Between Novel Transnasal and Surface Temperature-Modulating Devices. Neurocrit Care. 2023 Dec;39(3):639-645. doi: 10.1007/s12028-023-01793-3. Epub 2023 Jul 27. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Transnasal Thermal Regulating Device | Consented subjects will undergo cooling via transnasal thermal regulating device for a period of 8 to 24 hours Transnasal Thermal Regulating Device: Placement of transnasal thermal regulating device to reduce temperature in febrile patients for a period of 8 to 24 hours |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
30
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Transnasal Thermal Regulating Device | Consented subjects will undergo cooling via transnasal thermal regulating device for a period of 8 to 24 hours Transnasal Thermal Regulating Device: Placement of transnasal thermal regulating device to reduce temperature in febrile patients for a period of 8 to 24 hours |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Cooling Performance | Ability of transnasal thermal regulating device to reduce core body temperature within 4 hours of initiation | The primary efficacy analysis for cooling performance will be based on the evaluable populations of subjects who undergo cooling treatment with the COOLSTAT System. Analysis will be performed on treatment initiated and treatment completed populations. Subjects who achieve normothermia (core temperature ≤ 37.5 °C) within 4 hours of starting COOLSTAT treatment and maintain normothermia for the duration of the treatment will be determined to have been treated successfully. | Posted | Count of Participants | Participants | 4 hours |
|
Adverse events were collected during a 48 hour period, starting when the subject was placed on CoolStat, during the 24 hour cooling period, and for the 24 hour post-cooling observation period.
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Transnasal Thermal Regulating Device | Consented subjects will undergo cooling via transnasal thermal regulating device for a period of 8 to 24 hours Transnasal Thermal Regulating Device: Placement of transnasal thermal regulating device to reduce temperature in febrile patients for a period of 8 to 24 hours |
Not provided
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Shivering | Nervous system disorders | Systematic Assessment |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Director of Clinical Operations | CoolTech | 2036856352 | channan@cooltechcorp.com |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Jul 7, 2021 | May 25, 2023 | Prot_SAP_000.pdf |
Not provided
| ID | Term |
|---|---|
| D000083242 | Ischemic Stroke |
| D000083302 | Hemorrhagic Stroke |
| D005334 | Fever |
| D012640 | Seizures |
| D001928 | Brain Diseases, Metabolic |
| ID | Term |
|---|---|
| D020521 | Stroke |
| D002561 | Cerebrovascular Disorders |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Baltimore |
| Maryland |
| 21201 |
| United States |
| University of Texas, Houston | Houston | Texas | 77030 | United States |
| Participants |
|
| Age, Continuous | Mean | Standard Deviation | years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Ethnicity (NIH/OMB) | Count of Participants | Participants |
|
| Race (NIH/OMB) | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
|
|
| 0 |
| 30 |
| 0 |
| 30 |
| 15 |
| 30 |
| Insufficient cooling | Nervous system disorders | Systematic Assessment |
|
| Adverse effects on systemic blood pressure | Cardiac disorders | Systematic Assessment |
|
Not provided
Not provided
| D009422 |
| Nervous System Diseases |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
| D001832 | Body Temperature Changes |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D009461 | Neurologic Manifestations |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |